Evidence map›Paper›PMID 41988365›Full record

ArticleACS pharmacology & translational science2026

T‑Cell Immunoreceptor with Ig and Immunoreceptor Tyrosine-Based Inhibitory Motif Domains/Cluster of Differentiation 40 Cellular Nanovesicles Carrying Oxaliplatin Exhibited Superior Pancreatic Cancer Cells Therapy.

Wenlong Chen, Zining Zhang, Chuangchuang Zhao, Bo Wang, Xiang Liao, Qinghua Li, Dongqing Wang, Shengxiang Fu, Hsiang-I Tsai

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in ACS pharmacology & translational science, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Wenlong ChenInstitute of Medical Imaging and Artificial Intelligence, Jiangsu University, Zhenjiang 212001, China.
Zining ZhangInstitute of Medical Imaging and Artificial Intelligence, Jiangsu University, Zhenjiang 212001, China.
Chuangchuang ZhaoInstitute of Medical Imaging and Artificial Intelligence, Jiangsu University, Zhenjiang 212001, China.
Bo WangInstitute of Medical Imaging and Artificial Intelligence, Jiangsu University, Zhenjiang 212001, China.
Xiang LiaoInstitute of Medical Imaging and Artificial Intelligence, Jiangsu University, Zhenjiang 212001, China.
Qinghua LiInstitute of Medical Imaging and Artificial Intelligence, Jiangsu University, Zhenjiang 212001, China.
Dongqing WangInstitute of Medical Imaging and Artificial Intelligence, Jiangsu University, Zhenjiang 212001, China.
Shengxiang FuInstitute of Medical Imaging and Artificial Intelligence, Jiangsu University, Zhenjiang 212001, China.ORCID https://orcid.org/0000-0001-9755-0014
Hsiang-I TsaiInstitute of Medical Imaging and Artificial Intelligence, Jiangsu University, Zhenjiang 212001, China.ORCID https://orcid.org/0009-0008-6990-5453

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Profound chemoresistance and a highly immunosuppressive tumor microenvironment (TME) contribute to the high mortality rate of pancreatic ductal adenocarcinoma (PDAC). The overexpression of CD155 in PDAC facilitates its binding to the inhibitory receptor T-cell immunoreceptor with Ig and ITIM domains (TIGIT) on T-cells, thereby inducing immunosuppression. Herein, a biomimetic theranostic platform was constructed by encapsulating oxaliplatin (OXA)-loaded melanin nanoparticles (MNS) within engineered nanovesicles overexpressing TIGIT and cluster of differentiation 40 (CD40). These NVs serve a dual-modal function: they competitively antagonize the TIGIT/CD155 axis to bypass immune checkpoints and simultaneously trigger the CD40/CD40L pathway to provide potent costimulatory signals. This synergistic mechanism reverses T-cell exhaustion and enhances CD8

Indexed as

biomimetic drug deliverychemo-immunotherapyimmune evasionmagnetic resonance imaging (MRI)pancreatic ductal adenocarcinoma (PDAC)TIGIT/CD155 axis

Identifiers

PMID41988365
PMCPMC13077491

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.